A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease — FAME 3

Coronary Disease Clinical Trial

Official title:
Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to determine whether Fractional flow reserve (FFR, (coronary pressure wire-based index for assessing the ischemic potential of a coronary lesion)-guided percutaneous coronary intervention (PCI) in patients with multivessel coronary artery disease (CAD) will result in similar outcomes to coronary artery bypass graft surgery (CABG).

Clinical Trial Description

The FAME 3 trial is a multicenter, international, randomized, controlled noninferiority trial. All patients with multivessel CAD (not involving the left main) will be screened by the site's Heart Team (including but not limited to an interventional cardiologist, cardiac surgeon and research coordinator). If all agree that the patient can be treated either with FFR-guided PCI or CABG, and all inclusion criteria are met and no exclusion criteria are met, then the patient will be randomized. Baseline clinical, functional, laboratory and electrocardiographic data will be obtained. Patients will receive treatment within 4 weeks of randomization. Patients randomized to CABG will receive state of the art therapy at the discretion of the local surgeon with a strong emphasis on arterial revascularization. Patients undergoing PCI will have FFR measured with a St. Jude Medical coronary pressure wire across all lesions. If the FFR is ≤0.80, then PCI will be performed with the Medtronic Resolute Integrity drug-eluting stent (DES) as per usual routine. If the FFR is >0.80 then PCI will be deferred. All patients will receive medical therapy as per published guidelines. Patients will follow-up at 1 and 6 months, and 1 and 3 years with an evaluation of clinical status, functional status, medications and events. Follow-up may be extended to 5 years, if funding allows. Core lab analyses will include formal quantitative coronary angiography (QCA) of the baseline angiograms with calculation of the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score and Functional SYNTAX Score. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02100722
Study type	Interventional
Source	Stanford University
Contact
Status	Active, not recruiting
Phase	N/A
Start date	August 25, 2014
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Completed	`NCT05672862` - International Post-PCI FFR Extended Registry
Completed	`NCT04492423` - VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study
Completed	`NCT01205776` - EXCEL Clinical Trial	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed	`NCT00046410` - Comparison of the Risk of Stroke With On- Versus Off-Pump Coronary Artery Bypass Grafting	N/A
Recruiting	`NCT04390672` - Multivessel TALENT	N/A
Completed	`NCT02784873` - High Intensity Interval Training in UK Cardiac Rehabilitation Programmes	N/A
Completed	`NCT02948517` - Time Restricted Feeding for Weight Loss and Cardio-protection	N/A
Not yet recruiting	`NCT02895009` - Hemostatic Compression Patterns After Transradial Coronary Intervention	N/A
Recruiting	`NCT02859480` - Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI	Phase 4
Withdrawn	`NCT02418143` - A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope
Completed	`NCT02382731` - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Recruiting	`NCT01681381` - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization	N/A
Completed	`NCT02248415` - Administration of Warm Blood Cardioplegia With or Without Roller Pump	N/A
Recruiting	`NCT01207167` - Mediators of Atherosclerosis in South Asians Living in America
Completed	`NCT02088138` - Functional Electrical Stimulation in Cardiac Patients	N/A
Completed	`NCT02173067` - Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective	N/A
Completed	`NCT02133807` - Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.